Diaplus XR5 mg

Diaplus XR is an oral antidiabetic agent indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

• Established/FDA-approved use: Monotherapy for type 2 diabetes mellitus when hyperglycemia cannot be controlled by diet and exercise alone.
• Guideline-supported combination use: Diaplus XR is commonly used together with metformin, or occasionally with insulin or other antidiabetic agents, when a single agent does not achieve adequate glycemic control. Combination therapy requires medical supervision.
• Not indicated for type 1 diabetes mellitus or diabetic ketoacidosis (insulin is required in these situations).

Diaplus XR does not cure diabetes; it is used as part of an ongoing treatment plan alongside diet, exercise, and regular blood glucose monitoring.

Each immediate-release tablet contains Glipizide 5 mg or 10 mg as the active ingredient. Extended-release tablets of Glipizide are also available in some markets, typically as 2.5 mg, 5 mg, and 10 mg strengths. Exact strengths and available formulations may vary by manufacturer; check the product label for details.

Diaplus XR is a second-generation sulfonylurea, an oral blood-glucose-lowering drug used in the management of type 2 diabetes mellitus. It works mainly by stimulating the pancreas to release more insulin.

Diaplus XR is available as immediate-release tablets and, in some markets, as extended-release tablets. It is intended for use in adults with type 2 diabetes who still have some functioning pancreatic beta-cell activity; it has no role in type 1 diabetes.

Mechanism of Action

Glipizide lowers blood glucose by stimulating insulin release from functioning pancreatic beta cells. It binds to sulfonylurea receptors on the beta-cell membrane, closing ATP-sensitive potassium channels; this depolarizes the cell membrane, opens voltage-gated calcium channels, and triggers insulin secretion. With long-term use, Glipizide may also produce modest extrapancreatic effects that improve peripheral tissue sensitivity to insulin.

Pharmacokinetics

Glipizide is well absorbed from the gastrointestinal tract, with peak plasma concentrations reached within 1 to 3 hours for immediate-release tablets. It is highly protein-bound (>98%), extensively metabolized in the liver to largely inactive metabolites, and eliminated mainly via the kidneys, with a smaller amount excreted in feces. The elimination half-life is approximately 2 to 5 hours, though its glucose-lowering effect lasts up to 24 hours with once- or twice-daily dosing.

Diaplus XR immediate-release tablets should be taken about 30 minutes before a meal, typically breakfast, to match the timing of peak drug effect with the rise in blood glucose after eating. Extended-release tablets should be taken with breakfast and swallowed whole, without crushing, chewing, or splitting, as this can affect the controlled-release mechanism.

Take Diaplus XR at the same time each day, exactly as prescribed by the physician. Do not skip meals after taking a dose, as this increases the risk of hypoglycemia (low blood sugar). Do not stop, change the dose, or add other medicines without consulting a physician, as this can affect blood glucose control.

Diaplus XR has several clinically significant drug interactions:

• Drugs that increase hypoglycemia risk: NSAIDs, salicylates, sulfonamide antibiotics, certain antifungals (fluconazole, miconazole), and some other highly protein-bound drugs can potentiate the blood-glucose-lowering effect of Diaplus XR, increasing the risk of hypoglycemia.
• Beta-blockers: Can mask the warning signs of hypoglycemia (such as tremor and palpitations) and may prolong hypoglycemic episodes; use together with caution.
• Alcohol: Can potentiate the hypoglycemic effect of Diaplus XR and, in some patients, cause a disulfiram-like reaction (flushing, headache, nausea); alcohol intake should be limited.
• Colesevelam: Reduces absorption of Diaplus XR; Diaplus XR should be taken at least 4 hours before colesevelam.
• Drugs that raise blood glucose: Thiazide diuretics, corticosteroids, estrogens/oral contraceptives, and certain other agents may reduce the effectiveness of Diaplus XR and worsen glycemic control.

Always inform the physician or pharmacist about all prescription, over-the-counter, and herbal products being used together with Diaplus XR.

Most side effects of Diaplus XR are dose-related and reversible with dose adjustment.

• Common: Hypoglycemia (low blood sugar - the most frequent and clinically important side effect), nausea, diarrhea, dyspepsia, skin rash, and dizziness.
• Less common: Elevated liver enzymes, cholestatic jaundice (rare), photosensitivity.
• Rare but serious: Severe or prolonged hypoglycemia, hemolytic anemia (particularly in patients with G6PD deficiency - see Precautions), bullous pemphigoid (a blistering skin reaction), severe hypersensitivity reactions, and blood dyscrasias (such as leukopenia, thrombocytopenia, or agranulocytosis) have been reported rarely with sulfonylureas including Diaplus XR.

Patients should seek prompt medical attention for symptoms of hypoglycemia (sweating, shakiness, confusion, rapid heartbeat) or any signs of a severe skin reaction, jaundice, or unusual bleeding/bruising while taking Diaplus XR.

Pregnancy: The use of Diaplus XR in pregnancy is not recommended. Good glycemic control during pregnancy is important, and insulin is generally the preferred agent for managing diabetes in pregnant women. Diaplus XR should be used in pregnancy only if clearly needed and if a physician determines that the potential benefit justifies the potential risk to the fetus, including the risk of prolonged neonatal hypoglycemia if used near delivery. Always consult a physician before using Diaplus XR during pregnancy or if pregnancy is suspected or planned.

Lactation: It is not known whether Diaplus XR passes into human breast milk; because of the potential for hypoglycemia in a nursing infant, Diaplus XR is generally not recommended during breastfeeding. A physician may advise switching to insulin or another approach during lactation. Consult a physician before using Diaplus XR while breastfeeding.

• Hypoglycemia: The principal risk with Diaplus XR, particularly in elderly patients, those with renal or hepatic impairment, malnourished or debilitated patients, irregular meal patterns, increased physical activity, or concurrent alcohol use. Patients and caregivers should be educated to recognize and manage hypoglycemia symptoms.
• Cardiovascular risk: Some older studies of the sulfonylurea drug class raised concern about a possible increase in cardiovascular mortality compared with diet alone or with other treatments. This should be discussed with a physician, particularly in patients with known cardiovascular disease, when deciding on the use of Diaplus XR.
• G6PD deficiency: Sulfonylureas including Diaplus XR may cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency; consider a non-sulfonylurea alternative if possible.
• Adrenal, pituitary, or hepatic/renal insufficiency: These conditions increase the risk of hypoglycemia with Diaplus XR and require lower starting doses and closer monitoring.
• Loss of glycemic control during stress: Fever, trauma, infection, or surgery may cause loss of blood glucose control; temporary insulin therapy may be needed, and Diaplus XR may need to be withheld.
• Skin reactions: Rare cases of bullous pemphigoid have been reported with sulfonylureas including Diaplus XR; discontinue and seek medical attention if blistering skin lesions develop.

Overdose of Diaplus XR can cause severe and prolonged hypoglycemia, which may be life-threatening. Symptoms may include profuse sweating, confusion, tremor, seizures, and loss of consciousness.

Suspected overdose of Diaplus XR is a medical emergency. Seek immediate medical attention or contact emergency services/a poison control center right away. Do not wait for symptoms to worsen. Because the glucose-lowering effect of Diaplus XR can last much longer than expected, affected individuals require close medical monitoring, typically for at least 24 to 48 hours, even after initial improvement.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Elderly: Increased sensitivity to the glucose-lowering effect of Diaplus XR; start at a lower dose (2.5 mg/day) with careful monitoring for hypoglycemia (see Precautions).
• Renal impairment: Use with caution; start at a lower dose, as reduced clearance can increase the risk of hypoglycemia.
• Hepatic impairment: Use with caution and a lower starting dose, since Diaplus XR is extensively metabolized in the liver.
• Pregnancy and lactation: See Pregnancy and Lactation section above.
• Pediatric patients: See Pediatric Uses section below.
• G6PD deficiency: See Precautions and Warnings section above.

Diaplus XR is typically used long-term as part of ongoing management of type 2 diabetes mellitus, alongside diet and exercise. There is no fixed treatment duration; the physician will periodically review blood glucose control (including HbA1c) and may adjust the dose, add other antidiabetic medicines, or discontinue Diaplus XR based on response, tolerability, and changes in the patient's condition. Diaplus XR should not be stopped abruptly without medical advice, as this can lead to loss of blood glucose control.

C

The safety and efficacy of Diaplus XR have not been established in pediatric patients. Diaplus XR is not recommended for use in children or adolescents with diabetes mellitus. Management of diabetes in pediatric patients should follow specific pediatric treatment guidelines and be supervised by a physician experienced in pediatric diabetes care.